Your browser doesn't support javascript.
loading
Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies.
Ortiz-Genga, Martín F; Cuenca, Sofía; Dal Ferro, Matteo; Zorio, Esther; Salgado-Aranda, Ricardo; Climent, Vicente; Padrón-Barthe, Laura; Duro-Aguado, Iria; Jiménez-Jáimez, Juan; Hidalgo-Olivares, Víctor M; García-Campo, Enrique; Lanzillo, Chiara; Suárez-Mier, M Paz; Yonath, Hagith; Marcos-Alonso, Sonia; Ochoa, Juan P; Santomé, José L; García-Giustiniani, Diego; Rodríguez-Garrido, Jorge L; Domínguez, Fernando; Merlo, Marco; Palomino, Julián; Peña, María L; Trujillo, Juan P; Martín-Vila, Alicia; Stolfo, Davide; Molina, Pilar; Lara-Pezzi, Enrique; Calvo-Iglesias, Francisco E; Nof, Eyal; Calò, Leonardo; Barriales-Villa, Roberto; Gimeno-Blanes, Juan R; Arad, Michael; García-Pavía, Pablo; Monserrat, Lorenzo.
Afiliación
  • Ortiz-Genga MF; Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain; Health in Code SL, A Coruña, Spain. Electronic address: martin.ortiz@healthincode.com.
  • Cuenca S; Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Dal Ferro M; Cardiovascular Department, Azienda Ospedaliero - Universitaria Ospedali Riuniti, Trieste, Italy.
  • Zorio E; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Salgado-Aranda R; Hospital Universitario de Burgos, Burgos, Spain.
  • Climent V; Hospital General Universitario de Alicante, Alicante, Spain.
  • Padrón-Barthe L; Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
  • Duro-Aguado I; Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Jiménez-Jáimez J; Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Hidalgo-Olivares VM; Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • García-Campo E; Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Lanzillo C; Policlinico Casilino, ASL Roma B, Rome, Italy.
  • Suárez-Mier MP; Instituto Nacional de Toxicología y Ciencias Forenses, Madrid, Spain.
  • Yonath H; Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.
  • Marcos-Alonso S; Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
  • Ochoa JP; Health in Code SL, A Coruña, Spain.
  • Santomé JL; Health in Code SL, A Coruña, Spain.
  • García-Giustiniani D; Health in Code SL, A Coruña, Spain.
  • Rodríguez-Garrido JL; Health in Code SL, A Coruña, Spain; Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
  • Domínguez F; Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
  • Merlo M; Cardiovascular Department, Azienda Ospedaliero - Universitaria Ospedali Riuniti, Trieste, Italy.
  • Palomino J; Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Peña ML; Hospital Universitario Virgen del Rocio, Sevilla, Spain.
  • Trujillo JP; Health in Code SL, A Coruña, Spain.
  • Martín-Vila A; Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Stolfo D; Cardiovascular Department, Azienda Ospedaliero - Universitaria Ospedali Riuniti, Trieste, Italy.
  • Molina P; Servicio de Patología, Instituto de Medicina Legal, Valencia, Spain.
  • Lara-Pezzi E; Myocardial Pathophysiology Area, Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain; National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • Calvo-Iglesias FE; Complexo Hospitalario Universitario de Vigo, Vigo, Spain.
  • Nof E; Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.
  • Calò L; Policlinico Casilino, ASL Roma B, Rome, Italy.
  • Barriales-Villa R; Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain; Complexo Hospitalario Universitario de A Coruña, Servizo Galego de Saúde (SERGAS), Universidade da Coruña, A Coruña, Spain.
  • Gimeno-Blanes JR; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Arad M; Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.
  • García-Pavía P; Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain; Francisco de Vitoria University, Madrid, Spain.
  • Monserrat L; Instituto de Investigación Biomédica (INIBIC), A Coruña, Spain; Health in Code SL, A Coruña, Spain.
J Am Coll Cardiol ; 68(22): 2440-2451, 2016 Dec 06.
Article en En | MEDLINE | ID: mdl-27908349
BACKGROUND: Filamin C (encoded by the FLNC gene) is essential for sarcomere attachment to the plasmatic membrane. FLNC mutations have been associated with myofibrillar myopathies, and cardiac involvement has been reported in some carriers. Accordingly, since 2012, the authors have included FLNC in the genetic screening of patients with inherited cardiomyopathies and sudden death. OBJECTIVES: The aim of this study was to demonstrate the association between truncating mutations in FLNC and the development of high-risk dilated and arrhythmogenic cardiomyopathies. METHODS: FLNC was studied using next-generation sequencing in 2,877 patients with inherited cardiovascular diseases. A characteristic phenotype was identified in probands with truncating mutations in FLNC. Clinical and genetic evaluation of 28 affected families was performed. Localization of filamin C in cardiac tissue was analyzed in patients with truncating FLNC mutations using immunohistochemistry. RESULTS: Twenty-three truncating mutations were identified in 28 probands previously diagnosed with dilated, arrhythmogenic, or restrictive cardiomyopathies. Truncating FLNC mutations were absent in patients with other phenotypes, including 1,078 patients with hypertrophic cardiomyopathy. Fifty-four mutation carriers were identified among 121 screened relatives. The phenotype consisted of left ventricular dilation (68%), systolic dysfunction (46%), and myocardial fibrosis (67%); inferolateral negative T waves and low QRS voltages on electrocardiography (33%); ventricular arrhythmias (82%); and frequent sudden cardiac death (40 cases in 21 of 28 families). Clinical skeletal myopathy was not observed. Penetrance was >97% in carriers older than 40 years. Truncating mutations in FLNC cosegregated with this phenotype with a dominant inheritance pattern (combined logarithm of the odds score: 9.5). Immunohistochemical staining of myocardial tissue showed no abnormal filamin C aggregates in patients with truncating FLNC mutations. CONCLUSIONS: Truncating mutations in FLNC caused an overlapping phenotype of dilated and left-dominant arrhythmogenic cardiomyopathies complicated by frequent premature sudden death. Prompt implantation of a cardiac defibrillator should be considered in affected patients harboring truncating mutations in FLNC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN / Taquicardia Ventricular / Filaminas / Mutación / Cardiomiopatías Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: J Am Coll Cardiol Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN / Taquicardia Ventricular / Filaminas / Mutación / Cardiomiopatías Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Child / Child, preschool / Female / Humans / Infant / Male / Middle aged Idioma: En Revista: J Am Coll Cardiol Año: 2016 Tipo del documento: Article Pais de publicación: Estados Unidos